Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis.

ABSTRACT:

Objective

To analyze the incidence and risk of hypertension associated with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in cancer patients and provide reference for clinicians.

Methods

We used R software to conduct a meta-analysis of phase II/III randomized controlled trials (RCT) on PARP inhibitors for cancer treatment published in PubMed, Embase, Clinical Trials, Cochrane Library and Web of Science from inception to July 29th, 2022.

Results

We included 32 RCTs with 10,654 participants for this meta-analysis. For total PARP inhibitors, the incidence and risk ratio of all-grade hypertension were 12% and 1.22 (95% CI: 0.91-1.65, P = 0.19, I² = 81%), and the incidence and risk ratio of grade 3-4 hypertension were 4% and 1.24 (95% CI: 0.74-

SUBMITTER: Chen X 

PROVIDER: S-EPMC9887889 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature